Sinogene
Latest round
- Series B
Last raised
- Aug 2021
Total raised
- Undisclosed
Investors
- 5
About Sinogene
Established in 2012 and based in Beijing, China, Sinogene operates as a biotechnology company that focuses on pet cloning and gene editing. The company provides services of cat cloning, dog cloning, horse cloning, and cell preservation. The gene preservation (GP) consists in storing the pet genetic material so that it can be used even after decades. The Genetic preservation is accomplished by freezing the initial cell, tissue or germ plasma in the liquid nitrogen with low temperature.
Who invested in Sinogene
5 investors across 3 rounds
See all investors in Sinogene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Sinogene
Who invested in Sinogene?
Sinogene has 5 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Sinogene raised?
Sinogene has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Sinogene last raise money?
Sinogene's most recent round on record is a Series B, in Aug 2021.
What does Sinogene do?
Established in 2012 and based in Beijing, China, Sinogene operates as a biotechnology company that focuses on pet cloning and gene editing.
Where is Sinogene headquartered?
Sinogene is headquartered in Beijing, China.
Which VCs invest in companies like Sinogene?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Sinogene's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Sinogene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.